Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Operating Expenses (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Operating Expenses for 2 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 6.99% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.6 million through Dec 2025, up 133.91% year-over-year, with the annual reading at $16.8 million for FY2025, 6.23% down from the prior year.
  • Operating Expenses for Q4 2025 was $4.1 million at Neuphoria Therapeutics, down from $5.7 million in the prior quarter.
  • The five-year high for Operating Expenses was $5.8 million in Q2 2025, with the low at $3.0 million in Q1 2025.